医学课件:肝细胞癌(英文版).ppt

上传人:王** 文档编号:178188 上传时间:2023-03-21 格式:PPT 页数:34 大小:6.10MB
下载 相关 举报
医学课件:肝细胞癌(英文版).ppt_第1页
第1页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第2页
第2页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第3页
第3页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第4页
第4页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第5页
第5页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第6页
第6页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第7页
第7页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第8页
第8页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第9页
第9页 / 共34页
医学课件:肝细胞癌(英文版).ppt_第10页
第10页 / 共34页
亲,该文档总共34页,到这儿已超出免费预览范围,如果喜欢就下载吧!
资源描述

《医学课件:肝细胞癌(英文版).ppt》由会员分享,可在线阅读,更多相关《医学课件:肝细胞癌(英文版).ppt(34页珍藏版)》请在优知文库上搜索。

1、Hepatocellular carcinomaEpidemiology HCC is the seventh most common cancer worldwide, and the third leading cause of cancer-related deaths. More than 600,000 new cases worldwide annually (50% in China) Over 80% of HCCs occur in developing countries sub-Saharan Africa, southeast Asia, and east Asia I

2、ncidence decreased in developing countries and increased in developed countriesYang JD, et al. Nature Rev 2010Global variation in incidence of HCCYang JD, et al. Nature Rev 2010Etiology Hepatitis B: 50% HCC attributed to HBV worldwide Around 100 times higher for incidence of HCC in carriers than non

3、 carriers Hepatitis C: leading cause of HCC in Western countries and Japan Aflatoxin B: synergistic factor with HBV in China and sub-Saharan Africa Alcoholic liver disease: second most common risk factor for HCC after HCV in USA Nonalcoholic steatohepatitis (NASH): an emerging risk factor in develop

4、ed countriesPrevention Vaccination of HBV Reduced HCC incidence after universal vaccination of newborn babies Lamivudine treatment reduced incidence of HCC in hepatitis B or resultant cirrhosis Prevention of HCV transmission No vaccination for HCV Infection control measures in high risk practices (s

5、creening blood donors, use of disposable needles, thorough sterilization of surgical instruments) Interferon and ribavirin for hepatitis CPathology of HCC Differentiation Edmondson grade: I, II, III, IV Portal vein invasion Micro vessel, macro vessel (portal vein, hepatic vein, Inferior vena cava) M

6、etastasis Distant metastasis: lung, lymph nodule, bone, adrenal gland, brain)Tumor markers Alpha-fetoprotein (AFP) HCC: 60% 70% with elevated AFP Others: Active Hepatitis, liver cirrhosis Liver metastasis: Gastric cancer, pancreatic cancer, kidney cancer, embryonic tumors des- -carboxy prothrombin (

7、DCP)Imagines Ultrasonography Dynamic computed tomography (CT) Magnetic resonance imagine (MRI) AngiographySurveillance of HCC Individuals high risk for HCC Hepatitis men over 40 years, women over 50 years Patients with persistently or intermittently elevated alanine transaminase (ALT)levels Liver ci

8、rrhosis Hepatitis B or C related Alcoholic liver disease Hemochromatosis Primary biliary cirrhosis How to carry out the screening Ultrasonography in combination with serum HCC marker, alpha-fetoprotein (AFP), every 6 monthsDiagnosis American Association for the study of liver Diseases (AASLD) Lesion

9、 1.0cm, with HCC features (enhancement in artery phase and washout in venous phase) on one of Dynamic imagines (CT or MRI) Biopsy Diagnosis of HCCBruix J and Sherman M, Hepatology 2011Diagnosis of HCC Liver cirrhosis CT/MRI Or biopsyStaging systems Barcelona Clinic liver Cancer (BCLC) Cancer of the

10、liver Italian Program (CLIP) TNM (tumor, node and metastasis) Okuda Japanese Integrated staging score (JIS) systemsBCLC stageBruix J and Llovet JM, Lancet 2009Differential diagnosis Liver metastasis Colorectal, pancreatic, breast, lung; Intrahepatic cholangiocarcinoma Angioma Liver cysts Liver Absce

11、ss TreatmentSurgical treatment Surgical resection liver transplantationTransarterial chemoembolizaionLocal ablation Percutaneous ethanol injection (PEI) Radiofrequency ablation (RFA)RadiationSyctemic therapyChemotherapy, immunotherapy, molecular target therapySorafenib Sorafenib in advanced HCCMedia

12、n sur 6.5m vs 4.2mP=0.014Median time to progress 2.8m vs 1.4mP=0.0005Cheng AL et al. Lancet Oncol 2009Prognosis Tumor stage Size, nodules, portal vein involvement, metastasis Biomarkers Liver function Child-Pugh ECOG performanceThanks UltrasonographyMRIT1WT2WArtery phaseVenous phaseCTNon enhancement

13、, Enhancement in artery phase wash out in venous phaseangiographyPancreatic cancer metastasis to the liverIntrahepatic cholangiocarcinomaangiomaLiver cystSurgical resection n 5-y OS transplantation 468 75.7% surgical resection samll liver cancer 5059 57.0%large liver cancer 4860 30.3%Long-term survi

14、val of HCC treated with surgical resection and transplantation (1958-2009)Transarterial chemoembolizationPercutaneous ethanol injectionRadiofrequency ablationRFA for HCCSmall HCC treated with radiofrequency ablation(zhongshan hospital n=864)5cm: Medial survival 42m 5-year survaval rate: 34.7%3cm: Medial survival 62m 5-year survval rate:50.6%P0.0001

展开阅读全文
相关资源
猜你喜欢
相关搜索

当前位置:首页 > 医学/心理学 > 医学影像

copyright@ 2008-2023 yzwku网站版权所有

经营许可证编号:宁ICP备2022001189号-2

本站为文档C2C交易模式,即用户上传的文档直接被用户下载,本站只是中间服务平台,本站所有文档下载所得的收益归上传人(含作者)所有。装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。若文档所含内容侵犯了您的版权或隐私,请立即通知装配图网,我们立即给予删除!